A 65-year-old man after valve replacement experiences a rapid fall in platelets with swelling of a limb; what should be investigated and what therapy is indicated?

A 65-year-old man after valve replacement experiences a rapid fall in platelets with swelling of a limb; what should be investigated and what therapy is indicated?

• A. HIT; administer direct thrombin inhibitor
• B. Postoperative bleeding; administer plasma
• C. HIT; administer LMWH
• D. Platelet disorder; administer platelets

Answer: (A)

HIT with thrombosis is the likely issue here. After valve surgery, exposure to heparin can trigger an immune reaction where antibodies form against the heparin–platelet factor 4 complex. That drives platelet activation, a rapid drop in platelets, and paradoxical clotting, which explains the limb swelling as a thrombotic complication rather than simple postoperative bleeding. The correct approach is to stop all heparin immediately and start a non–heparin anticoagulant. A direct thrombin inhibitor, such as argatroban or bivalirudin, is indicated because it safely prevents further thrombosis without fueling HIT. This targeted therapy addresses the underlying immune-mediated prothrombotic state. Testing should be pursued to confirm HIT, typically with PF4–heparin antibody testing and a functional assay (like the serotonin release assay), while imaging helps evaluate the extent of limb thrombosis. Warfarin is avoided in the acute phase because it can worsen microvascular thrombosis in HIT and is usually started only after platelets recover. Platelet transfusion or plasma would not treat the HIT process and might worsen thrombosis, and continuing with LMWH is avoided because it can perpetuate HIT.

HIT with thrombosis is the likely issue here. After valve surgery, exposure to heparin can trigger an immune reaction where antibodies form against the heparin–platelet factor 4 complex. That drives platelet activation, a rapid drop in platelets, and paradoxical clotting, which explains the limb swelling as a thrombotic complication rather than simple postoperative bleeding.

The correct approach is to stop all heparin immediately and start a non–heparin anticoagulant. A direct thrombin inhibitor, such as argatroban or bivalirudin, is indicated because it safely prevents further thrombosis without fueling HIT. This targeted therapy addresses the underlying immune-mediated prothrombotic state.

Testing should be pursued to confirm HIT, typically with PF4–heparin antibody testing and a functional assay (like the serotonin release assay), while imaging helps evaluate the extent of limb thrombosis. Warfarin is avoided in the acute phase because it can worsen microvascular thrombosis in HIT and is usually started only after platelets recover. Platelet transfusion or plasma would not treat the HIT process and might worsen thrombosis, and continuing with LMWH is avoided because it can perpetuate HIT.